Wire · opportunities
Novo, Orbis sign up to $1.4 billion deal to develop oral drugs
◆ Sectors
◆ Geography
◆ Source
◆ Verified
Fusion42 · 17 September 2026 · Fusion42 review
Orbis Medicines and Novo Nordisk have signed a drug discovery and licensing deal worth up to $1.4 billion to develop oral therapies for cardiometabolic diseases using Orbis' AI-enabled platform for macrocycle drug discovery. Novo will also make a strategic investment in Orbis, aiming to transform treatments traditionally administered via injections into oral forms.
This Wire brief sits within Fusion42's coverage of Biotech, and 2 sources have reported it.
◆ ◆ The Wire takeaway
You need to recognise the jump in AI-driven drug discovery turning injectables into oral medicines. Investors and developers in biotech should prepare for rising competition and partnership opportunities in macrocycle therapeutics now backed by major pharma.
◆ Coverage
2 sources · 17 Sep 2026
◆ Related on Wire
◆ Topics